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46 Simultaneous detection of common cystic ﬁbrosis mutations by
reverse-hybridization teststrips
H. Puehringer1, B. Rauscher1, C. Oberkanins1. 1ViennaLab Diagnostics GmbH,
Vienna, Austria
Cystic ﬁbrosis (CF) is one of the most common autosomal recessive disorders, with
an incidence of approximately 1 in 3000 live births in Caucasians. CF is caused by
mutations in the cystic-ﬁbrosis transmembrane regulator (CFTR) gene, encoding a
chloride channel protein. Patients with classical CF accumulate viscous mucus in the
respiratory and gastrointestinal system, leading to chronic lung infections, excess
salt loss, difﬁculties in digestion, and ultimately to a shortened life expectancy. More
than 1000 CFTR mutations have been described to date, the majority being very rare
or private. The most frequent mutation worldwide F508del accounts for 30−72%
of CF chromosomes depending upon ethnicity. Overall there is great heterogeneity
in the remaining pathogenic mutations, as type and distribution vary substantially
between populations.
We have developed a reverse-hybridization assay (Cystic Fibrosis StripAssay) for the
rapid and simultaneous analysis of common CFTR mutations. The assay covers 23
mutations recommended by the ACMG plus 10 additional ones prevalent in different
parts of Europe, as well as the IVS8 polyT (5T/7T/9T) variants. Thus a coverage of
70−93% can be obtained almost all over Europe. The test is based on multiplex DNA
ampliﬁcation and hybridization to teststrips presenting a parallel array of allele-
speciﬁc oligonucleotide probes for each mutant and wild-type allele. The procedure
is rapid, simple and convenient, accessible to automation and requires very small
amounts of samples, which is of particular importance for prenatal diagnosis and
newborn screening. Currently the Cystic Fibrosis StripAssay is validated in a multi-
center study.
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Since 1998 sweat tests has been done among 810 CF suspecting children and 45
adult men with idiopathic spermatogenesis failure. The molecular genetic testing
of CFTR gene mutation was performed among 470 persons with CF suspicion. 145
CF probands were detected. Nineteen different CFTR gene mutations were found
and about 85% of CFTR alleles have been identiﬁed. Chloride concentration in
sweat was in range from 7.8 to 108.2mmol/l and 16.7% of analysis were positive.
Among children with positive sweat test in 71% patients two CFTR gene mutations
were detected, in 21% − one mutation and in 7.6% − no one mutations has
been identiﬁed. No one case of pseudo positive sweat test results we have had.
Among children with normal sweat test range one case of F508del heterozygous
was identiﬁed: 3 years boy with maldigestion and without pulmonary disorders.
This patient is under observation but diagnosis of CF was not conﬁrmed. Among
adult men with idiopathic spermatogenesis failure in 60% cases sweat test was
normal (<40mmol/l), in 33% borderline and in 6.1% (>60mmol/l) positive. CFTR
gene mutations analysis revealed F508del mutation and 5T allele in 5% of patients
with normal and in 18% of patients with borderline sweat test. 2 man with high
level of chloride concentration (79.5 and 90.1mmol/l) have no CF symptoms except
aspermia. One of them is heterozygous for F508del, other one is negative for all
analyzed CFTR mutations. The results have shown insufﬁciency of the revealing
the CF cases (~13 per year to 40 expected) and need of CF neonatal screening.
Sweat test is important for Cystic Fibrosis diagnosis establishing as well for CFTR
related diseases identiﬁcation.
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Pre-implantation genetic diagnosis (PGD) on polar bodies and/or blastomeres has
become an established clinical approach for prevention of genetic disorders as CF.
We evaluated a model of parthenogenetic activation (PA) of human oocytes in
order to assess the feasibility of CF-PGD in our laboratory, using an experimental
tool independent from fertilization. After partial zona pellucida dissection, ﬁrst
polar bodies (PB1) were removed from spare donated metaphase-II oocytes and
transferred to lysis buffer. PA was conducted on biopsied oocytes through exposure
to ionomycin in culture medium. After 18 hours oocytes showing one pronucleus
and the second polar body (PB2) were considered activated: PB2s were biopsied
and treated as PB1s. PGD molecular procedure involved a ﬂuorescent multiplex
PCR analysis of highly polymorphic short-tandem repeat (STR) markers, to identify
the haplotype associated with the maternal mutation. A panel of 10 STR markers
ﬂanking CFTR gene were selected to ensure sufﬁcient informativity in all cases.
Cases with less than three informative markers were excluded. 21 oocytes were
selected from seven women. 20 of them were subjected to PA, and 15 oocytes
extruded the PB2. Three out of 15 PB2 did not get any ampliﬁcation product. Out
of 12 PB1 analyzed, 10 were heterozygous and 2 homozygous for the markers
evaluated, thus resulting in a percentage of recombination of 83%. We observed a
frequency of allele drop out (ADO) of 5.1% (3/59). The model of PA conﬁrms that
PGD for CF is feasible; however, in our study, the high recombination in CFTR
gene limits to 17% the possibility to perform PGD using only the PB1, according
to the Italian legislation.
